Latest QLTI CC:
With the obvious interest here in QLTI, I want to share the perspective from Charly Travers who recently recommended QLTI to Motley Fool subscribers. Like posters here, he is aware that QLTI does not have a good moat in treatment of AMD. His keeness on the company is heavily based on its imminent acquisition with Atrix. Recognizing the threat to QLTI posed by competition and thin pipeline, he likes the fit with Atrix, a small, profiatble drug company with a deeper pipeline.